Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 12/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166044 | 0.92 | TAS2R14 (0.42) | TAS2R14MEN1KMT2APOLBKDM4E | |
| SCHEMBL3172148 | 0.82 | MEN1 (0.37) | TAS2R14MEN1KMT2APOLBKDM4E | |
| SCHEMBL3160997 | 0.82 | MEN1 (0.44) | TAS2R14MEN1KMT2APOLBKDM4E | |
| SCHEMBL14790783 | 0.81 | MEN1 (0.43) | TAS2R14MEN1KMT2A | |
| SCHEMBL25090182 | 0.80 | SCN9A (0.41) | ALOX12TAS2R14MEN1KMT2APOLB | |
| SCHEMBL29669070 | 0.79 | MEN1 (0.40) | ALOX12MEN1KMT2APOLBKDM4E | |
| SCHEMBL15466024 | 0.79 | MEN1 (0.40) | ALOX12MEN1KMT2APOLBKDM4E | |
| SCHEMBL3117965 | 0.78 | TAS2R14 (0.49) | TAS2R14MEN1KMT2A | |
| SCHEMBL14790529 | 0.78 | TAS2R14 (0.48) | TAS2R14 | |
| SCHEMBL18352243 | 0.77 | SCN1A (0.36) | ALOX12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-8357711-B2 | Heterocyclic sulfonamides as inhibitors of ion channels | PFIZER LIMITED (GB) | 2013-01-22 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | ALOX12 1302/4885TAS2R14 1594/4885MEN1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.